Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 31:2:7.
doi: 10.1186/s40842-016-0024-x. eCollection 2016.

Lipoprotein (a), an independent cardiovascular risk marker

Ramesh Saeedi  1   2 , Jiri Frohlich  1   2
Affiliations
Review

Lipoprotein (a), an independent cardiovascular risk marker

Ramesh Saeedi et al. Clin Diabetes Endocrinol. .

Abstract

Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level; however, there are few treatment options for the management of patients with elevated Lp(a). Several new medications for Lp(a) are under development. PCSK9 inhibitors, apolipoprotein (a)-antisense, and apolipoprotein(B-100)-antisense mipomersen have shown promising results. Lp(a) reduction will continue to be an active area of investigation.

Keywords: Coronary artery disease (CAD); Lipoprotein(a) [Lp(a)]; Niacin; Statins.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kassner U, Schlabs T, Rosada A. Lipoprotein(a)-An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015;18:263–7. doi: 10.1016/j.atherosclerosissup.2015.02.039. - DOI - PubMed
    1. Jacobson TA. Lipoprotein(a). Cardiovascular Disease, and Contemporary Management. Mayo Clin Proc. 2013;88(11):1294–311. doi: 10.1016/j.mayocp.2013.09.003. - DOI - PubMed
    1. Nielsen LB, Grønholdt ML, Schroeder TV, et al. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997;17(5):905–11. doi: 10.1161/01.ATV.17.5.905. - DOI - PubMed
    1. Erqou S, Kaptoge S, Perry PL, et al. Emerging Risk Factors Collaboration, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–23. doi: 10.1001/jama.2009.1063. - DOI - PMC - PubMed
    1. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333–43. doi: 10.1016/j.clinbiochem.2003.12.007. - DOI - PubMed